The Latest Cardiac and Vascular News
Proactive, personalized monitoring of myocardial fitness at regular intervals, powered by MCG technology, represents paradigm shift in the prevention of heart disease City of Mason’s Biohealth Corridor selected as home of first ever CardioFlux Imaging Institute MASON, Ohio, Dec. 11, 2024…
Designation represents progress for patients with suspected Coronary Microvascular Dysfunction as the FDA recognizes disease’s debilitating impacts and the lack of effective non-invasive options for efficient diagnosis MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted […]
New additions to leadership signal commercial readiness and an expanding clinical roadmap MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its […]
Mithril Capital-led Series C to launch 5-minute noninvasive ischemia assessment requiring no pharmaceuticals, no exercise, and no radiation. MASON, Ohio–(BUSINESS WIRE)–Genetesis, the market leader in next-generation biomagnetic imaging, has announced that it has closed $17.5 million in Series C Financing. The round was led by Mithril Capital with participation from […]
MASON, Ohio–(BUSINESS WIRE)–Genetesis, Inc. announced today that its flagship product, CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome. CardioFlux®, the most advanced commercially available magnetocardiograph (MCG), […]
– Strategic investments round out $9.2M Series B round of financing – Sajid Malhotra joins Genetesis Board of Directors MASON, Ohio, May 7, 2020 /PRNewswire/ — Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFlux™ imaging, today announced several important updates. The company has closed significant strategic investments from TDK […]
Initial study shows Genetesis, Inc.’s CardioFlux Magnetocardiograph (MCG) has potential to rule patients out for Coronary Artery Disease. MASON, Ohio, Jan. 30, 2020 /PRNewswire/ — Undiagnosed chest pain sends 8-10 million Americans to Emergency Departments annually, making it the second most common complaint. Emergency physicians must rapidly identify patients whose chest pain is […]
MASON, Ohio–(BUSINESS WIRE)–Genetesis, a medical technology company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has received FDA 510(k) clearance for its cardiac imaging platform. The platform pairs the CardioFlux™ Magnetocardiograph with the integrated Faraday Analytical Cloud™ (FAC). “This milestone provides emergency room physicians […]
MASON, Ohio–(BUSINESS WIRE)– Genetesis, a medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has closed an oversubscribed round of $7.5M in Series A financing. CincyTech led the round with participation from existing investors including Mark Cuban’s Radical Investments, and new investors including […]
